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The host response against foreign materials designates the biocompatibility of intravenously adminis-
tered microcapsules and thus, widely affects their potential for subsequent clinical use as artiﬁcial
oxygen/drug carriers. Therefore, body distribution and systemic parameters, as well as markers of
inﬂammation and indicators of organ damage were carefully evaluated after administration of short-
chained poly (vinyl alcohol, (PVA)) solution or poly (ethylene glycol (PEG))-shielded perﬂuorodecalin-
ﬁlled poly (D,L-lactide-co-glycolide, PFD-ﬁlled PLGA) microcapsules into Wistar rats. Whereas PVA
infusion was well tolerated, all animals survived the selected dose of 1247 mg microcapsules/kg body
weight but showed marked toxicity (increased enzyme activities, rising pro-inﬂammatory cytokines and
complement factors) and developed a mild metabolic acidosis. The observed hypotension emerging
immediately after start of capsule infusion was transient and mean arterial blood pressure restored to
baseline within 70 min. Microcapsules accumulated in spleen and liver (but not in other organs) and
partly occluded hepatic microcirculation reducing sinusoidal perfusion rate by about 20%.
Intravenous infusion of high amounts of PFD-ﬁlled PLGA microcapsules was tolerated temporarily
but associated with severe side effects such as hypotension and organ damage. Short-chained PVA
displays excellent biocompatibility and thus, can be utilized as emulsiﬁer for the preparation of drug
carriers designed for intravenous use.
& 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Artiﬁcial blood substitutes are urgently needed to guarantee the
rising blood supply of the population. Packed red cells are inade-
quately available, require cold storage conditions, display a short shelf-
life and are associated with problems such as blood group compat-
ibility and risk of transmission of various diseases [1]. Thus,
alternatives such as perﬂuorocarbon-based oxygen carriers have
moved into the focus of medical research. Perﬂuorocarbons (PFCs)
are ﬂuorinated hydrocarbons dissolving effectively the main respira-
tory gases oxygen and carbon dioxide in a manner that depends
linearly on the partial pressure of the correspondent gas [2]. Their
known chemical and biological inertness, due to the strength of the
carbon-ﬂuorine bonds, make them perfect candidates for medical
applications but also evoke galenical problems [2]. So far, PFCs were
always engineered as oil-in-water emulsions (inwhich PFC constitutes
the oil phase) rendering them blood-compatible for intravenous
administration [1]. However, typical problems such as biological
incompatibility of the used emulsiﬁers, coalescence and ﬂocculation
of emulsion droplets leading to an increased particle size could not be
satisfactorily eliminated [3]. We tried to overcome these problems by
engineering biocompatible poly (ethylene glycol)-coated poly (D,L-
lactide-co-glycolide) microcapsules (PLGA microcapsules) with a PFC
core [4,5]. PLGA and poly (ethylene glycol) (PEG) are metabolizable,
harmless compounds, that are approved by the Food and Drug
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Administration for internal use in humans, thus representing ideal raw
materials for the design of intravenously applicable drug carriers [5].
To our knowledge, in vivo data are missing about intravenously
administered microparticles made of PEG and PLGA, although these
two materials are very common substances that have been excessively
explored. Moreover, there generally exist only very few in vivo data
about microparticles designed for intravenous application [6,7]. Cer-
tainly this is because the design of microcarrier systems for intravas-
cular use represents a special challenge [7]. In difference to ultrasonic
contrast agents or usual drug carriers, the dedication of microcapsules
as artiﬁcial oxygen carriers requires the safe intravenous application of
very high amounts of the pharmaceutical (1/10–1/3 of the blood
volume for oxygen carriers, in contrast to 1/20,000 for ultrasonic
contrast agents [8]).
The principal suitability of PFCs as artiﬁcial oxygen carrier is widely
recognized in the literature [1,9] and the general feasibility of
intravenous administration of our PFD-ﬁlled PLGA microcapsules has
already been demonstrated [5]. Favorably, the pharmaceutical agent
PFD must only be encapsulated and the intact capsule wall must allow
an effective gas exchange. In the present work we focused on the
detailed investigation of side effects caused by the intravenous
administration of very high amounts of PFD-ﬁlled PLGA microcapsules
to further the use as artiﬁcial oxygen carriers, because until now, none
of the current formulations of hemoglobin-based or perﬂuorocarbon-
based artiﬁcial oxygen carriers can be infused without toxic effects in
sufﬁcient amounts in order to preserve aerobic metabolism in all
tissues [10].
2. Materials
2.1. Chemicals
Poly (D,L-lactide-co-glycolide) (PLGA) (50:50) produced by LAC-
TEL (B6013-2P, inherent viscosity in chloroform 0.67 dl/g) was
purchased from NRC Nordmann Rassmann (Hamburg, Germany).
Poly (D,L-lactide-co-glycolide) (50:50) copolymers covalently
attached with poly (ethylene glycol) (PEG) (RESOMER PEG Sample
CR, RGPd50155, inherent viscosity in chloroform 0.50 dl/g) were
obtained from Boehringer Ingelheim (Ingelheim, Germany). Nile
red, ﬂuorescein isothiocyanate-dextran 150,000 (FITC-dextran)
and poly (vinyl alcohol) (PVA, Mw 9000–10,000, 80% hydrolyzed)
came from Sigma (Deisenhofen, Germany). Perﬂuorodecalin (PFD)
was from F2 Chemicals (Preston, United Kingdom). Isoﬂurane
(Forenes) was obtained from Abbott (Wiesbaden, Germany),
ketamine 10% from Ceva (Düsseldorf, Germany) and lidocaine
(Xylocains 1%) from AstraZeneca (Wedel, Germany). Portexs
catheters (0.58 mm i.d./0.96 mm o.d.) were purchased from Smiths
Medical International (Hythe, United Kingdom). Medical oxygen
was obtained from Air Liquide (Düsseldorf, Germany), ringer
solution from Fresenius (Bad Homburg, Germany) and sterile NaCl
0.9% Ecoﬂac from B. Braun, Melsungen, Germany. Parafﬁn (Para-
plast Tissue Embedding Medium REF 501,006) was from McCor-
mick Scientiﬁc (St. Louis, USA). Cryomatrix (Shandon Cryomatrix)
was purchased from Thermo, Fisher Scientiﬁc (Waltham, USA) and
Mounting Medium (Vectashield Hard Set Mounting Medium with
DAPI, H-1500) from Vector Laboratories (Burlingame, USA).
3. Methods
3.1. Capsule preparation
PFD-ﬁlled PEG-PLGA microcapsules (diameter of 1.5 7 0.8 mm)
were prepared by an emulsion-evaporation procedure as
described before [5]. Brieﬂy, an organic solution of 100 mg PLGA
(92% PLGA, 8% PEG-PLGA) and 100 ml PFD in 6 ml methylene
chloride was emulsiﬁed into 20 ml of an aqueous solution of 1%
PVA by using an Ultraturrax T25 (IKA Werke, Staufen, Germany)
operating with an S25KV-25G-IL dispersing tool at a velocity of
10,200 rpm. For preparation of PEG-PLGA microspheres (unﬁlled
polymer particles with a diameter of 1.5 7 0.8 mm) Ultraturrax
velocity was changed to 5400 rpm. The used methylene chloride
was evaporated under magnetic stirring. Microcapsules (indepen-
dent of the capsule type) were centrifuged (199.6 g, 20 min,
Biofuge primo R, Heraeus, Hanau, Germany) and washed three
times with sterile 0.9% NaCl. The ﬁnal pellet was resuspended in
10 ml sterile 0.9% NaCl and subsequently ﬁltered using a 2.7 mm
pore size syringe ﬁlter (Whatman, Dassel, Germany). For the
preparation of PFD-ﬁlled PEG-PLGA microcapsules with a lower
size of 1 7 0.5 mm, Ultraturrax velocity was changed to 14,000
rpm and a 1.6 mm pore size syringe ﬁlter (Whatman, Dassel,
Germany) was used as described previously [11].
For evaluating frozen sections of various organs after contact
with PFD-ﬁlled PEG-PLGA microcapsules (diameter of 1.5 mm), 100
ml of a stock solution of Nile red (0.057 mg/ml in methylene
chloride) were added to the methylene chloride phase prior to
emulsiﬁcation [12].
All capsules were prepared freshly and were used the same day
for animal experiments.
3.2. Animal experiments
3.2.1. Animals
A total number of 60 male Wistar rats (Rattus norvegicus, 448
7 23 g) were obtained from the central animal unit of the Essen
University Hospital. Animals were kept under standardized con-
ditions of temperature (22 7 1 1C), humidity (55 7 5%), and 12/
12-h light/dark cycles with free access to food (ssniff-Spezialdiä-
ten, Soest, Germany) and water. All animals received humane care
according to the standards of Annex III of the directive 2010/63/EU
of the European Parliament and of the Council of 22 September
2010 on the protection of animals used for scientiﬁc purposes [13].
The experimental protocol was approved by the local committee
for animal protection based on the local animal protection act.
3.2.2. Anesthesia, analgesia, and surgical procedure
Rats were anesthetized with isoﬂurane (2.0% in 100% medical
O2 at 4.0 l/min for induction, 1.5–2.0% isoﬂurane in 100% medical
O2 at 1.0 l/min throughout the experiment) through face masks
connected to a vaporizer (Isoﬂuran Vet. Med. Vapor; Draeger,
Luebeck, Germany) and received ketamine (50 mg/kg body
weight, subcutaneously) into the right chest wall for analgesia.
After local lidocaine administration (5 mg/kg body weight sub-
cutaneously), a median skin-deep inguinal incision of about 2 cm
was made along the right groin and a Portex catheter (0.58 mm ID,
0.96 mm OD) was placed within the right femoral artery and the
right femoral vein. Each catheter was ﬁxed with a surgical suture.
At the end of experiment, animals were sacriﬁced by resection of
the heart, liver, spleen, lung, kidney, brain, M. gastrocnemius and
small intestine under deep isoﬂurane anesthesia.
3.2.3. Study groups
In the main setting we compared three experimental groups.
One group (n ¼ 14) received PFD-ﬁlled PLGA microcapsules (1.5
mm), one group (n ¼ 9) was medicated with a sterile solution of
0.25% PVA (maximum possible concentration of PVA remainder
from capsule synthesis) and one group (n ¼ 9) was treated with
0.9% NaCl. All solutions were infused continuously for 30 min into
the right femoral vein using a syringe pump (20 ml/kg body
weight  h). The total volume of 20 ml/kg body weight was
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chosen, because this is a typical volume (5–30 ml/kg body weight)
for studies with oxygen carriers [2,14]. The short infusion time of
30 min was selected as pre-hospital treatment of trauma or other
severely injured patients (the potential target population for
artiﬁcial oxygen carriers) should not exceed 30–40 min [15,16].
After the stop of infusion, 12 animals were monitored for 4 h. As
high blood volumes were required for determination of cytokines
and complement factors, for 20 animals the main setting was
shortened from 270 to 150 min and 90 min, respectively (NaCl and
PVA each n ¼ 3 and PFD-ﬁlled PLGA microcapsules 1.5 mm n ¼
4 for both time points).
The frozen section procedure (see below) was performed in an
additional setting only slightly differing from the main setting (see
section frozen section procedure) with 2 groups, one receiving 1
mm PFD-ﬁlled PLGA microcapsules (n ¼ 2) and one receiving 1.5
mm PFD-ﬁlled PLGA microcapsules (n ¼ 2).
For the assessment of hepatic microcirculation, in vivo micro-
scopy (intravital microscopy, IVM) was performed in an extra,
independent setting (see section in vivo microscopy) with
4 groups: PFD-ﬁlled PLGA microcapsules (1 and 1.5 mm), PLGA
microspheres (1.5 mm) and 0.9% NaCl each n ¼ 6.
3.2.4. Biomonitoring
Systolic blood pressure, diastolic blood pressure and mean
arterial blood pressure (MAP) were recorded continuously via
the femoral artery catheter that was connected to a pressure
transducer and displayed on a monitor. Ringer solution was
delivered at 3 ml/h to keep the catheter functional. Heart rates
were determined from systolic blood pressure spikes. The breath-
ing rate was determined by counting the ventilation movements
per minute every 10 min. The core body temperature of the rats
was continuously monitored using a rectal sensor; cooling below
37 1C was prevented by both an underlying thermostat-controlled
operating table and by covering the animals with aluminum foil.
3.2.5. Assessment of blood and plasma parameters
Blood samples (0.5 ml) for both blood gas analysis and the
monitoring of released enzymes activities in plasma in the main
setting (see study groups) were taken from the femoral artery
catheter before the start of infusion (after catheterization of A.
femoralis) and subsequently 90, 150, 210 and 270 min after start of
the infusion using a 2 ml syringe containing 80 IU electrolyte-
balanced heparin (Pico50, Radiometer Medical, Br⊘nsh⊘j, Den-
mark). Inﬂammation parameters were determined only at the end
of experiment in each setting at 90 min, 150 min or 270 min. For
each blood sampling animals were substituted with a 0.5 ml bolus
of 0.9% NaCl via the femoral artery (with the additional effect to
keep the catheter functional). In order to obtain plasma, blood was
centrifuged at 4000g for 15 min at room temperature. The gained
plasma was stored at 4 1C until use (maximal within 4 h).
3.2.5.1. Blood gas analysis. Arterial blood pH, oxygen and carbon
dioxide partial pressures (pO2, pCO2), base excess (BE), bicarbonate
and lactate were assessed with a blood gas analyzer (ABL 715,
Radiometer, Copenhagen, Denmark).
3.2.5.2. Enzyme activities. The plasma activity of lactate dehy-
drogenase (LDH) as a general marker of cell injury, creatine kinase
(CK) as a marker for muscle cell injury, aspartate aminotransferase
(ASAT) and alanine aminotransferase (ALAT) as markers for
hepatocyte injury as well as the plasma creatinine concentration
as a marker of renal function were determined using a fully
automated clinical chemistry analyzer (Vitalab Selectra E, VWR
International, Darmstadt, Germany) using commercially available
reagent kits (DiaSys, Holzheim, Germany).
3.2.5.3. Inﬂammation parameters. The plasma concentration of the
cytokines Interferon-gamma (IFN-γ), Interleukin-1alpha (IL-1α),
IL-1β, IL-4, IL-5, IL-6, IL-10 and tumor necrosis factor alpha (TNF-α)
were determined by using a rat-speciﬁc multiplex bead
suspension array (Bio-Plex Cytokine Assay) in conjunction with a
Bio-Plex Array Reader (Bio-Rad, Muenchen, Germany).
The plasma concentration of complement factors 3 (C3) and 4a
(C4a) were assessed with rat-speciﬁc ELISA kits (Rat complement
fragment 4a ELISA kit, Cusabio, Wuhan, China, and Rat Comple-
ment Factor 3, GenWay Biotech Inc, San Diego, CA, USA) according
to the manufacturer's instructions.
3.2.6. Assessment of microcirculation and physiological functions
3.2.6.1. In vivo microscopy. In vivo microscopy analysis (IVM) was
performed with a Leica DMLM epiﬂuorescence microscope (Leica
Microsystems, Wetzlar, Wetzlar, Germany, 160 magniﬁcation).
Anesthesia Analgesia, and surgical procedures were the same as in
the setting without IVM. The left lateral liver lobe was exteriorized
on a specially designed stage 40 min after catheterization of the
femoral vessels. The abdominal cavity was kept moist. One
milliliter/kilogram body weight of ﬂuorescein isothiocyanate-
dextran 150,000 (FITC-dextran, 5% solution in 0.9% NaCl) was
injected intravenously for ﬂuorescent staining of liver
microcapillaries [17]. Fifteen min after application of FITC-
dextran, PFD-ﬁlled PLGA microcapsules (either 1.5 or 1 mm),
PLGA microspheres (1.5 mm) or 0.9% NaCl solution were infused
continuously for 30 min into the right femoral vein using a syringe
pump (20 ml/kg body weight  h). During the measurement,
animals were biomonitored continuously as described.
The following parameters were determined in ﬁve randomly
selected acinar areas and postsinusoidal venules:
(1) Diameters of sinusoids and postsinusoidal venules by an image
analysis software (Kappa ImageBase 2.8.2.11051, Kappa Optro-
nics GmbH, Gleichen, Germany).
(2) The number of perfused vessels (the ratio of perfused sinu-
soids to all sinusoids visible in a deﬁned acinar area) (%) by
analyzing full video sequences by an examiner blinded to the
experimental groups.
3.2.6.2. Frozen section procedure. In order to evaluate the in vivo
distribution of PFD-ﬁlled PLGA microcapsules, cryosections of liver,
spleen, lung, kidney, brain, heart and M. Gastrocnemius were
prepared. Anesthesia, analgesia, and surgical procedures were the
Fig. 1. Effect of capsule infusion on mean arterial blood pressure. PFD-ﬁlled PLGA
microcapsules (1.5 mm), 0.25% PVA or 0.9% NaCl were infused for 30 min (light gray,
20 ml/kg body weight  h). The values plotted are mean 7 SEM of 14-6
(capsules), 9-3 (PVA and NaCl) individual experiments, *p o 0.05 compared to
NaCl group for time-matched data (0–90 min).
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same as in the setting without frozen section procedure. Fluorescent-
stained microcapsules (1.5 or 1 mm) were infused continuously for 30
min into the right femoral vein using a syringe pump (20 ml/kg body
weight  h) 40 min after catheterization of the femoral vessels.
Microcapsules were allowed to circulate for 40 min. Afterwards the
organs were cryopreserved and frozen. Cryosections of about 5 mm
were prepared and nuclei were stained with 40,6-diamidin-2-
phenylindol (DAPI). Evaluation of the in vivo distribution of the
infused microcapsules was succeeded by ﬂuorescence microscopy
(200 magniﬁcation), using an Axio Imager.A1 microscope
equipped with an AxioCam MRc camera and an AxioVision Rel.
4.6 software (Zeiss, Jena, Germany).
3.2.7. Histological evaluation of the spleen, liver, lung and small
intestine
For histological examinations liver, spleen, small intestine and
lung were resected. Subsequent to its resection, the small intestine
Fig. 2. Organ distribution of PFD-ﬁlled PLGA microcapsules and effect of capsule infusion on tissue damage. PFD-ﬁlled PLGA microcapsules (1.5 mm) were stained with Nile
red and were allowed to circulate for about 40 min within the blood circulation, before organs were cryopreserved and frozen. Cryosections of spleen (A), liver (B) and lung
(C) were prepared and nuclei were stained with DAPI (blue) for ﬂuorescence microscopic analysis (200 magniﬁcation). For assessment of the effect of capsule infusion on
tissue damage, unstained PFD-ﬁlled PLGA microcapsules (1.5 mm) were infused for 30 min (20 ml/kg body weight  h). Microscopic assessment (100 magniﬁcation) of
spleen (D), liver (E) and lung tissue (F).
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was immediately cut into 10 pieces of equal length (9.5–10.5 cm).
The median liver lobe, the spleen and the forth segment of the
small intestine (serially numbered from jejunum to ileum) were
ﬁxed in formalin (10% neutral buffered) for 24–48 h. Before the
thorax was opened, the lung was ﬁlled with 5 cm3 air via a canula
after tracheotomy, then harvested, ﬁlled with formalin (5 ml) to
ensure complete unfolding and ﬁnally submersed in formalin, as
the other organs. Parafﬁn-embedded sections were stained with
hematoxylin eosin and evaluated in a blinded manner. Histological
changes in the small intestine were scored on a scale from 0 to 8
[adaptation of the Park/Chiu system [18,19]]. Using light micro-
scopy, spleen sections (100 and 400 magniﬁcation) were
assessed for integrity of red and white pulp, lung sections
(100 and 400 magniﬁcation) were scanned for swelling of
alveolar walls caused by bleeding or accumulation of water into
the tissue and alveolar walls, liver sections (100 and 400
magniﬁcation) were investigated for disruption of parenchyma
and vacuoles using the AxioVision Rel. 4.6 software (Zeiss, Jena,
Germany).
3.3. Statistics
Biochemical assays were run in duplicate unless stated other-
wise. Data are expressed as mean values 7 SEM. Comparisons
among multiple groups were performed with one-way analysis of
variance (ANOVA) either for nonrecurring or for repeated mea-
sures followed by Dunnett (Figs. 1, 3, S1, S2, S4 and S6) or Sidak
(Fig. 4) post-hoc analysis by using the graph pad prism 6.02
software (GraphPad Software, La Jolla, USA). Only data presented
in the supporting information Fig. S5 was analyzed with two-way
ANOVA followed by Dunnett post-hoc analysis. A p-value o0.05
was considered to indicate signiﬁcance.
4. Results
4.1. Systemic reactions
4.1.1. Hemodynamics and other systemic parameters
MAP in the NaCl control group remained in the physiological
range (90–120 mmHg) throughout the whole experiment (Fig. 1).
MAP in the PVA group differed only slightly from control (91–100
mmHg). In sharp contrast, animals receiving PFD-ﬁlled PLGA
microcapsules with a diameter of 1.5 mm experienced a signiﬁcant,
temporary descent of MAP to 57 mmHg shortly after start of
infusion, regaining baseline conditions after about 70 min. In all
three groups heart rates stayed constant at about 300 bpm (Fig.
S1A). In the PVA and microcapsule groups breathing rates
increased from baseline level (about 50 breaths per min) to about
60 breaths per min from 0 to 80 min normalizing afterwards to
baseline level (Fig. S1B). The body temperature of all animals was
inconspicuous and persisted around 37 1C (Fig. S1C).
4.1.2. Acid–base and metabolic status
The pH of all animals was slightly acidotic at about 7.3 (Fig.
S2A). pCO2 was mildly elevated to about 55 mmHg (Fig. S2B) while
pO2 was inconspicuous and varied around 500 mmHg in all three
experimental groups (Fig. S1D). Base excess diminished somewhat
in the NaCl and PVA treated animals, but did not move out of the
physiological range (þ3 to 3 mmol/l, Fig. S2C). However, the
animals treated with microcapsules suffered from a signiﬁcant
decline from –0.9 mmol/l (0 min) to 5.9 mmol/l (120 min),
compared to NaCl-infused animals. Blood lactate concentration in
the NaCl and PVA groups increased only slightly to 1.2 and
1.0 mmol/l, respectively (Fig. S2D). In contrast, in the animals
treated with microcapsules, lactate concentration signiﬁcantly
increased. Values doubled from 0.8 mmol/l (0 min) to 1.7 mmol/l
(120 min) ﬁnally descending to control level at the end of the
experiment (Fig. S2D).
4.2. Organ distribution and organ/tissue damage
Assessment of cryosections revealed an excessive accumulation
of PFD-ﬁlled PLGA microcapsules (1.5 mm) in spleen and liver
(Fig. 2A–B) but displayed very few capsules in other organs, i.e.,
lung (Fig. 2C), brain, kidney, heart and M. Gastrocnemius (Fig. S3).
Identical results were obtained after infusion of 1 mm-sized PFD-
ﬁlled PLGA microcapsules (data not shown).
Infusion of NaCl or PVA did not affect plasma activities of the
enzymes ALAT, ASAT, CK and LDH (Fig. 3). In contrast, after
infusion of PFD-ﬁlled PLGA microcapsules plasma activities of
ALAT (3.6-fold), ASAT (6-fold), CK (5-fold) and LDH (24-fold) were
signiﬁcantly elevated if compared to the NaCl group at the end of
experiment (Fig. 3). Creatinine concentrations oscillated around
0.7 mg/dl in all three experimental groups (Fig. S4).
Hematoxylin-eosin-staining revealed changes of spleen and
liver architecture. Compared with NaCl- or PVA-infused animals
(free of pathological indications), spleens of animals treated with
PFD-ﬁlled PLGA microcapsules showed beginnings of dissolving
tissue structures of white pulp and red pulp (Fig. 2D). Liver
structures were still distinguishable but offered some vacuoles
(Fig. 2E), while lung tissue was intact and did not display any sign
of thickened alveoli walls (Fig. 2F).
Microscopic investigations of the mucosa of the fourth segment
of the small intestine did not reveal distinct pathological changes
in any group (data not shown). In contrast, in the group of animals
treated with PFD-ﬁlled PLGA microcapsules macroscopic assess-
ment of the serosa revealed some petechiae scattered over the
entire jejunum.
4.3. Effects on inﬂammation parameters
Plasma concentrations of IL-1α, IL-1β, IL-6, IL-10 and TNF-α
displayed similar characteristics. After the infusion of PFD-ﬁlled
PLGA microcapsules, pro-inﬂammatory cytokines (such as IL-1α,
IL-1β, IL-6, TNF-α) were strongly elevated compared to NaCl
controls, whereas infusion of PVA did not provoke any immune
response (Fig. 4A–H). Notably, 90 min after begin of microcapsule
infusion a clear increase of IL-10 took place and persisted until the
end of the experiment (Fig. 4F). Irrespective of the treatment
group, plasma levels of both IL-4 (o14.1 pg/ml) and IFN-γ (o35.0
pg/ml) were unaffected and only very small amounts of IL-5
(o113.0 pg/ml, not signiﬁcantly different between the treatment
groups) were released (Fig. 4C/D/G).
The application of NaCl did not alter the concentration of
complement factor 3 (C3) in plasma. Only at 270 min, C3 level in
the group treated with PFD-ﬁlled PLGA microcapsules was
reduced signiﬁcantly when compared to the NaCl group at 270
min (Fig. 4I). Infusion of NaCl or PVA did not affect the plasma
amount of complement factor 4a (C4a) either. In both groups all
values stayed below the assay’s detection limit (Fig. 4J). In contrast,
after infusion of PFD-ﬁlled PLGA microcapsules, the plasma con-
centration of C4a increased and differed signiﬁcantly from the
respective NaCl control at all time-points monitored (Fig. 4J).
4.4. Effects on microcirculation
The diameters of sinusoids and postsinusoidal venules
increased about 23% and 20% already 10 min after start of infusion
of PFD-ﬁlled PLGA microcapsules (1.5 mm and 1 mm, respectively)
whereas infusion of PLGA microspheres caused a decrease of
vessel diameter of 15% compared to NaCl control group (Fig. S5).
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During the following 20 min of infusion, diameters of sinusoids
and postsinusoidal venules of all microcapsule treated animals
normalized, thereby reaching the baseline level at the end of the
infusion (Fig. S5).
After infusing 0.9% NaCl, the number of perfused vessels and
MAP remained at baseline levels (100%, 100 mmHg, respectively,
Fig. 5A). In contrast, at the very beginning of the infusion of PFD-
ﬁlled PLGA microcapsules (1.5 mm) MAP (mmHg) and the number
of perfused vessels (%) decreased to about 60 mmHg/50% from
baseline. Only MAP regenerated during the following observation
time, whereas the number of perfused vessels only reached 80% of
baseline level (Fig. 5B). Infusion of PFD-ﬁlled PLGA microcapsules
(diameter 1 mm) revealed identical results as obtained with 1.5 mm
microcapsules (Fig. S6). After treatment with PLGA microspheres
MAP did not decrease but stayed in the physiological range (85–
100 mmHg) throughout the whole experiment (similar to the NaCl
group) and the number of perfused vessels slowly decreased
leveling off at 80% of baseline level after 150 min (Fig. 5C).
5. Discussion
5.1. Study rationale
Blood losses up to a hemoglobin level of 10 g/dl are generally
well tolerated by patients. Intervention with red blood cell
concentrates or artiﬁcial oxygen carriers becomes necessary when
hemoglobin level would further decrease. If and how many red
blood cell concentrates are transfused (in default of approved
artiﬁcial oxygen carriers) not only depends on the individual
patient’s condition but also on the hospital’s practice, whereas at
a hemoglobin decrease below 6 g/dl transfusion of red blood cell
concentrates is generally indicated [20]. If transfusion is inalien-
able, until now, usually 2 or more red blood cell concentrates are
required, as the average increase in hemoglobin level per unit red
blood cell concentrate is only 1.0 g/dl [21]. Therefore, the tolerance
of high quantities of foreign particles in the intravascular system is
a prerequisite for the successful use of microcapsules as artiﬁcial
oxygen carriers and implies both, the occurrence and the monitor-
ing of new toxicity proﬁles. So far the infusion of 1247 mg PFD-
ﬁlled PLGA microcapsules/ kg body weight is clearly higher than
common dosing of intravenously administered polymeric pharma-
ceuticals (ca. 23 mg/kg body weight [7], 440 mg/kg body weight
[22]). Not only quantitatively but also in relation to the blood
volume the amount of infused microcapsules is high (1/6 of the
blood volume, assuming the calculation of the rat’s blood volume
proposed by Lee et al. [23]), which is in the same order of
magnitude as demonstrated for PLA50 nanoparticles (also 1/6)
[22] but much higher than similar-sized microparticles (1/28) [7]
or ultrasound contrast agents (1/20,000) [8]. Assuming a mean
blood volume of 4–6 l for humans, 1/6 (0.67–1.0 l) corresponds to
2.4–3.6 red blood cell concentrates (0.28 l).
Fig. 3. Effect of capsule infusion on organ/tissue damage: ALAT (A), ASAT (B), LDH (C) and CK (D). PFD-ﬁlled PLGA microcapsules (1.5 mm), 0.25% PVA or 0.9% NaCl were
infused for 30 min (light gray, 20 ml/kg body weight  h). The values plotted are mean 7 SEM of 14-6 (capsules), 9-3 (PVA and NaCl) individual experiments, *p o 0.05
compared to NaCl group.
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Fig. 4. Effect of capsule infusion on release of cytokines and complement factors. PFD-ﬁlled PLGA microcapsules (1.5 mm), 0.25% PVA or 0.9% NaCl were infused for 30 min
(20 ml/kg body weight  h). The values plotted are mean 7 SEM of 6-4 (capsules) or 3 (PVA and NaCl) individual experiments, *p o 0.05 compared to NaCl group. The
detection limit of the used ELISA was 0.08 ng/ml. Note: logarithmic scale was used for Fig. 4E, F and H. C4a level in NaCl and PVA groups at all time-points measured were
below detection limit.
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5.2. Effects on MAP
Transient systemic hypotension after infusion of PFC-based
artiﬁcial oxygen carriers has been described long ago for PFC-
based emulsion systems [24,25] and latterly also for capsule-based
PFC-containing systems [26]. This undesirable side effect has been
attributed to the action of the emulsiﬁer without [27,28] or in
combination with the PFC [29]. In order to safely exclude any
emulsiﬁer-caused side effects, a control group receiving PVA only
(without microcapsules) was implemented, although the short-
chained PVA used in this study is known as biocompatible and
eliminable via the kidneys [30,31]. As MAP remained stable in the
PVA group (Fig. 1), our results are comparable to the data of
Ingram et al., suggesting, that only the combined action of PFC and
emulsiﬁer is responsible for transient hypotension [29]. Further-
more, hypotension only occurred after application of PFD-ﬁlled
PLGA microcapsules (Fig. 1, Fig. 5B) but not after application of
PFD-free PLGA microspheres (Fig. 5C). Due to the fact that
transient hypotension was also described after intravenous appli-
cation of PFD-ﬁlled poly(n-butyl-cyanoacrylate) nanocapsules
[26], transient hypotension may be a general complication of
perﬂuorocarbon-based products irrespective of the type of gale-
nical packaging (emulsion or capsule) of the oxygen carrier.
The proposed mechanism for this transient hypotension would
be the prompt activation of the complement system leading to the
release of vasoactive substances [28,29,32,33]. As anaphylatoxins
can regulate vasodilation and increase permeability of small blood
vessels [34,35], a decline of C3 concentration in plasma and
increase of the anaphylatoxin C4a after infusion of microcapsules
(but no changes after treatment with PVA) are in line with this
hypothesis (Fig. 4I,J). Activation of both, the classical and the
alternative pathway of the complement system are possible by
contact of blood with artiﬁcial particles [36,37]. The clear increase
of C4a (not part of the alternative pathway [38,39]), should
support an involvement of the classical pathway. Activation of
the classical pathway (initiated by the adsorption of plasma
proteins such as IgG and albumin) can also amplify the alternative
pathway mediating primarily the reaction against foreign bioma-
terials [40]. Since PEG-shielding can only partly reduce protein
adsorption on surfaces of PLGA particles [5,37], adsorbed IgG may
mediate activation and binding of C3b to the capsules’ surface as
proposed by Nilsson et al. [38]. A complement activation-related
pseudoallergy (CARPA) that is already conﬁrmed for different
nanoparticles, polymers and emulsiﬁers such as Cremophor EL
or Tween [41,42] was not responsible for transient hypotension
(Figs. S1 and S2). Even though in contradiction to CARPA symp-
toms in pigs and dogs [41,43] this is not surprising, as rats are
especially insensitive to CARPA [44].
Another explanation for transient hypotension would be an
involvement of nitric oxide-mediated (NO) pathways. Short- and
long-term regulation of NO production in response to shear stress
on the endothelial membrane of vasculature (as potentially caused
by the heavy-weight PFD-ﬁlled microcapsules) is well-known
[45,46]. Additionally, the formation of relatively stable S-
nitrosothiols (believed to act as biological metabolites and carriers
of NO) in the blood in presence of perﬂuorocarbons (as PFD) can
induce NO releasevia synthesis of intermediates, that are highly
effective in nitrosating other compounds [47–49]. This process can
also be triggered by shear force on endothelial cells [50].
However, an effect on MAP evoked primarily by the release of
cytokines seems unlikely, although release of cytokines from
monocytes, macrophages and lymphocytes after contact with
PLGA is described in vitro and in vivo [51–54]. The cytokine proﬁle
after infusion of PFD-ﬁlled PLGA microcapsules (Fig. 4A–H) is in
line with in vitro data from mononuclear cells cultured in the
presence of poly-L-lactide [52] and macrophages cultured in the
presence of PLGA microparticles (diameter of 6.5 mm) [53]. The
strong release of IL-10 may counteract the effects induced by the
pro-inﬂammatory cytokines, avoiding an excessive immune
response by, among others, inﬂuencing production of TNF-α
[51,52]. Nevertheless a direct relation between release of cytokines
and transient hypotension cannot be propagated, as cytokine
levels in plasma remained elevated until the end of the experi-
ment (Fig. 4A–H), whereas MAP normalized after 70 min (Fig. 1,
Fig. 5B). Likewise, the reported appearance of allergic and anaphy-
lactic reactions to some PFC-containing emulsions [9] leading to
hypotension cannot be used as an argument in the present study
as the IL-5 level obtained after application of PLGA microcapsules
did not differ signiﬁcantly from corresponding NaCl control values
(Fig. 4D).
5.3. Effect on microcirculation and distribution pattern
Hepatic sinusoidal blood ﬂow depends among other factors on
MAP and sinusoidal diameter, whereupon reduced sinusoid dia-
meter causes impairment of sinusoidal blood ﬂow [55]. Decreased
number of perfused vessels is certainly mostly entailed by the
prompt and radical drop of MAP after application of PFD-ﬁlled
PLGA microcapsules (Fig. 5B), because undesirable artifacts due to
Fig. 5. Effect of capsule infusion on hepatic microcirculation. IVM was performed
to determine the number of perfused vessels of the hepatic microvascular system
after intravenous administration (30 min, light gray, 20 ml/kg body weight  h) of
either 0.9% NaCl (A), PFD-ﬁlled PLGA microcapsules (1.5 mm, B) or PLGA micro-
spheres (1.5 mm, C). The values plotted are mean 7 SEM of 6 individual
experiments.
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liver exteriorization and IVM handling on hepatic microcirculation
could be excluded (Fig. 5A). Additional aggravation by a reduced
sinusoidal diameter cannot be identiﬁed as driving force for this
decrease, since the diameter at this time was even increased from
baseline level; possibly be a sort of counteraction. Because both,
hypotension and increase of sinusoidal diameter were only tran-
sient and quickly restored to baseline level, the just partial
recovering of the number of perfused vessels probably indicates
a PFD-ﬁlled PLGA microcapsules-mediated obstruction of micro-
capillaries (Fig. 5B). The fact that the number of perfused vessels
dropped likewise but temporarily-delayed (synchronized with a
reduction of the sinusoidal diameter) while MAP remained in the
physiological range after treatment with microspheres, should
further substantiate the fractional occlusion of hepatic microcir-
culation by PLGA microcapsules (Fig. 5B). This can be veriﬁed by
the accumulation of PFD-ﬁlled PLGA microcapsules only in spleen
and liver (Fig. 2A and B). The same distribution pattern also applies
for intravenously administered PLGA nanoparticles [56] and 2 mm-
sized silicon dioxide particles [57]. While other investigators
additionally observed an accumulation of microparticles in lung
tissue [57,58], our results showed neither enrichment in that
organ nor swollen alveolar walls (Fig. 2C and F).
5.4. Effects on acid–base metabolism and tissue oxygenation
Persisting microcirculatory impairment can lead to tissue
hypoxia and the development of subsequent organ dysfunction
[55]. Thus, the function of oxygen carriers is to improve the
microcirculation as already established for a PFC-based emulsion
and a hemoglobin-based suspension [55,59]. However, animals
treated with PFD-ﬁlled PLGA microcapsules experienced a mild
metabolic acidosis (Fig. S2) corresponding to the data of Sedova
et al. describing the same phenomenon after infusion of a PFC-
containing emulsion [60].
Probably lactate formation in muscle tissue increases due to
transient hypotension and reduced number of perfused vessels of
sinusoids. This can entail an undersupply of affected tissue areas
with oxygen triggering anaerobic glycolysis [61]. The increase in
enzyme activities in plasma, such as LDH as a general marker of
cell injury and CK as a marker for muscle cell injury, should further
support the assumption of cellular damage (Fig. 3C and D). An
increased LDH level was also described after contact of silica
nanoparticles with human endothelial cells and after pulmonary
exposition of rats to polystyrene particles [62]. In contrast,
intravenous injection of nanoporous silicon microparticles pro-
voked only a mild increase in LDH plasma activity [63]. As these
data were obtained 24 h post injection of microparticles, they
differ from the acute response (only 4 h post infusion of PLGA
microcapsules) monitored in this study as expected. Reduced
perfusion and hypoxia also damaged liver and spleen tissue.
Pathological tissue alteration and increase in plasma activities of
liver tissue-associated enzymes such as ALAT and ASAT after
infusion of PFD-ﬁlled PLGA microparticles further emphasize liver
damage (Figs. 2 and 3). This matches data on PFC-containing
emulsions describing a transient increase of plasma transaminase
activities because of accumulation of emulsion droplets in Kupffer
cells [64].
The conventional in vivo degradation of PLGA to lactic and
glycolic acid in the presence of oxygen [65], with all metabolites
entering the tricarboxylic acid cycle (further degradation into H2O
and CO2) [66] or, the alternative elimination of glycolic acid via the
kidney [67] certainly were not the reason for the observed
acidosis, as PLGA is attributed with an in vivo degradation time
of 50–60 days [68]. Although this degradation process of PLGA is
primarily a hydrolytic process (drivable by enzymes, such as
trypsin, but not dependent on their presence [69]) contact with
blood (not containing the relevant enzymes) does not enhance the
degradation of PLGA microcapsules. In line with this, degradation
studies with PEG-PLGA capsules show a decay rate of only about
15% 1–3 h after intravenous administration [70] and studies with
PLGA ﬁlms describe a drop in pH only after an in vitro degradation
period of 30 days [71]. Hence, the impact of these degradation
mechanisms becomes more important in a later phase and thus,
cannot explain the observed mild, metabolic acidosis.
6. Conclusions
Generally, the infusion of high quantities of PFD-ﬁlled PLGA
microcapsules was tolerated as all animals survived the selected
observation period. Nevertheless, the ﬁndings of this study imply a
new toxicity proﬁle compromised with severe side effects that are
only partially described for other intravenously infused foreign parti-
cles and for the used materials such as PFD so far. As expected from
previous studies about the pharmacokinetics and biodisposition of
different PVAs [30,31], in the present investigation, short-chained PVA
was completely harmless in vivo during an observation time of 4 h.
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